Recursion CEO details novel Phase III endpoint for rare disease drug
Recursion Pharmaceuticals has secured alignment with the FDA on a novel endpoint for its planned Phase III trial of REC-4881,…
Recursion Pharmaceuticals has secured alignment with the FDA on a novel endpoint for its planned Phase III trial of REC-4881,…
While M&A appetite has been strong in 2026, deals are increasingly thwarted by valuation gaps, geopolitical uncertainty and greater selectivity among buyers. Reflecting on the year, industry experts at the…
London-based Ellipses Pharma said it might conduct an initial public offering (IPO) on home soil, an announcement that could mark the end for one of the longest ever dry spells…
Lineage Cell Therapeutics is acquiring fellow Californian biotech company NeuroAirmid Therapeutics – officially adding a novel Huntington’s disease therapy to its pipeline. Through this takeover, which saw Lineage outlay $4.7m…
AbbVie has forged a partnership worth up to $2.5bn with German biotech Disco Pharmaceuticals focused on bispecific cancer therapies for solid tumours. Through this agreement, AbbVie will hand over $40m…
In the same week that Pfizer’s CEO Albert Bourla reiterated China’s growing role in the global pharma industry, the company has ventured to the nation to sign a multi-billion-dollar licensing…
Over the past decade, there have been several core scientific and technological developments that have paved the way for a rare disease revolution – with new therapeutic modalities, in silico…